MCK Stock Recent News
MCK LATEST HEADLINES
Over the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in technology stocks and even more from the Magnificent 7, the idea of investing in low-growth dividend stocks loses some appeal.
McKesson (MCK) closed the most recent trading day at $679.33, moving +1.13% from the previous trading session.
IRVING, Texas--(BUSINESS WIRE)--Register to attend McKesson ideaShare, a premier community pharmacy annual education and networking event, in Nashville from July 10-13, 2025.
McKesson acquires 80% ownership in PRISM Vision Holdings, diversifying its business into the high-growth area of ophthalmology. The deal is to be accretive this year.
MCK IS UP OVER 14 POINTS AFTER THE TRADEPULSE ALERT
An aging U.S. population is increasing the demand for medication, and this company delivers.
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The ac.
In the most recent trading session, McKesson (MCK) closed at $672.99, indicating a +0.74% shift from the previous trading day.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.